Amgen's Evenity Faces CV Safety Gauntlet At US FDA Advisory Cmte.

 
• By Michael Cipriano

Narrower indication and a boxed warning for Amgen's osteoporosis drug romosozumab might be sufficient to permit approval.  

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers